Techdow is among the first few Chinese pharmaceutical companies that have built their own sales teams overseas. Techdow's enoxaparin sodium injection is currently sold to over 50 countries and regions across the world and included by the national insurance systems of 13 EU member states, United Kingdom, and Switzerland, winning broad recognition for the product globally.
China
United States
United Kingdom
Switzerland
Poland
France
Germany
Italy
Spain
Czech Republic
Austria
Danmark
Croatia
Finland
Portugal
Sweden
Canada
Brazil
Columbia
Peru
Chile
Paraguay
Bolivia
Albania
Bosnia and Herzegovina
Kosovo
Ukraine
Malaysia
Philippines
Vietnam
Kazakhstan
Saudi Arabia
UAE
Jordan
Palestine
Iraq
Sri Lanka
Uzbekistan
Madagascar
Macedonia
.jpg)
Serbia
El Salvador
DC00A99B13B4401689D3FCEAA6FE3CD7.jpg)
Indonesia
Montenegro
Australia
Brunei
Ecuador
Cyprus
Malta
Lithuania
Latvia
Estonia
Costa Rica
Techdow now operates in 7 countries across the globe
In 2005, Techdow's enoxaparin sodium injection (Prolongin®) became the first generic enoxaparin approved for China market by the National Medical Product Administration (NMPA, also formerly known as CFDA). In 2020, all SKUs of enoxaparin sodium injection (Prolongin®) marketed in China passed the Bioavailability Equivalence Evaluation of the Quality and Efficacy of Biosimilar, and became the first product that passed the evaluation in China at the time. In 2023, Techdow's enoxaparin sodium injection (Prolongin®) became the first enoxaparin product selected by the 8th Centralized National Procurement in China.
In 2016, Techdow’s enoxaparin sodium injection was approved in the EU as the company’s first branded biosimilar in the region and the company began to build local sales teams for the 5 major European markets (Poland, Italy, United Kingdom, Germany, Spain). As of 2024, Techdow has cumulatively sold approximately 660 million pre-filled syringes of its enoxaparin sodium injection in the European market1.
1. Based on 2017-2024 statistics from IQVIA database
As a drug and API supplier for a company granted marketing authorization for enoxaparin sodium injections, Techdow officially began supplying enoxaparin sodium injections to the U.S. market in 2020. In 2021, Techdow started building its own local sales team in the U.S. and subsequently began selling its heparin sodium injections in the country in 2022. In 2023, Techdow's enoxaparin sodium injection product (Enoxaparin Sodium Injection, USP) was approved by the U.S. Food and Drug Administration (FDA) and subsequently launched in the U.S. market.
Since 2009, Techdow's enoxaparin sodium injections began entering rest of the world, and have thus far obtained marketing authorizations in 39 countries and regions, including Argentina, Australia, Canada, New Zealand, Brazil, Saudi Arabia, and Malaysia, etc., and are being sold in 31 countries and regions. Techdow's business now covers North America, Central and South America, the Middle East, Southeast Asia, and the Balkans, and is widely recognized by medical experts and physicians in those markets.
